美东时间周三，莫德纳宣布撤回新冠和流感联合疫苗上市许可申请，以等待更多有效性数据。公司计划今年晚些时候重新提交申请，并附上独立流感疫苗试验结果。受此影响，莫德纳股价盘中下跌超6%。此前，FDA收紧新冠疫苗审批要求，对部分人群需提供随机对照临床试验结果。莫德纳表示将继续与FDA合作，确保美国人获得所需疫苗。分析认为，撤回申请对莫德纳扩大疫苗需求的战略构成干扰。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.